

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers are Required to Complete This Page

RECEIVED  
OFFICE OF THE SENATE

FILED 10 PM 12:51

1. Registrant Name Capitol Associates, Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported 426 C Street N.E.			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC 20002			
4. Contact Name Deb M. Hardy Havens	Telephone 202-544-1880	E-mail (optional) dh@capitolassociates.com	5. Senate ID # 8101-428
7. Client Name <input type="checkbox"/> Self Fred Hutchinson Cancer Research Center			6. House ID # 30813054

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☒

10. Check if this is a Termination Report ☐ ⇒ Termination Date \_\_\_\_\_

11. No Lobbying Activity ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<b>12. Lobbying Firms</b>  INCOME relating to lobbying activities for this reporting period was:  Less than \$10,000 <input type="checkbox"/>  \$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ 20,000 Income (nearest \$20,000)  Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>13. Organizations</b>  EXPENSES relating to lobbying activities for this reporting period were:  Less than \$10,000 <input type="checkbox"/>  \$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)  <b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options. <input type="checkbox"/> Method A. Reporting amounts using LDA definitions only <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code
--	---

Signature

*Debra M. Hardy Havens*

Printed Name and Title Debra M. Hardy Havens, CEO

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

H.R. 4577- A bill making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2001, and for other purposes (Consolidated Appropriations Act, 2001); Title II - Department of Health and Human Services. Secure support for the National Institutes of Health and the National Cancer Institute, and salary cap for research investigators.

S. 2553- A bill making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September, 30, 2001, and for other purposes; Title II - Department of Health and Human Services. Secure support for the National Institutes of Health and the National Cancer Institute and salary cap for research investigators.

H.R. 3656 - A bill making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September, 30, 2001, and for other purposes; Title II - Department of Health and Human Services. Secure support for the National Institutes of Health and the National Cancer Institute and salary cap for research investigators.

Tracked and monitored the following legislation:

- H.J. Res. 109 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 110 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 111 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 114 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 115 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 116 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 117 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 118 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 119 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 120 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 121 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 122 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 123 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 124 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 84 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 125 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 126 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 127 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 128 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 129 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.
- H.J. Res. 133 - Making further continuing appropriations for the fiscal year 2001, and for other purposes.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Marguerite Donoghue Baxter		<input type="checkbox"/>
Sara Mito		<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature \_\_\_\_\_

Printed Name and Title Debra M. Hardy Havens, CEO

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

Tracked and monitored the following legislation:

S. 2015 - Stem Cell Research Act of 2000. Tracked and reported on Congressional Hearings on stem cell research  
 Tracked and monitored the regulation process for NIH Guidelines for Research Involving Human Pluripotent Stem Cells  
 H.R. 1388/S.784 - Medicare Cancer Clinical Trial Coverage Act of 1999  
 H.R. 1798/S. 1813 - Clinical Research Enhancement Act of 1999  
 H.R. 2498 - Public Health Improvement Act ("minibus" of nine bills including the Clinical Research Enhancement Act)  
 H.R. 2621/S.1091 - Pediatric Research Initiative Act of 1999  
 H.R. 4365/S. 2868 - Children's Health Act of 2000  
 H.R. 4605 - Human Research Subjects Protections Act of 2000  
 S. 1010 - Medical Innovation Tax Credit for Clinical Testing Research. Tracked and monitored Congressional Hearings and White House and DHHS oversight of gene therapy research and clinical research  
 Tracked and monitored clinical research subject protection initiatives of the DHHS, including financial conflicts of interest, changes to the Declaration of Helsinki, research involving children, and research conduct.  
 S. 2038 - Medical Error Reduction Act of 2000  
 S. 2738 - Patient Safety and Errors Reduction Act  
 S. 2743 - Voluntary Error Reduction and Improvement in Patient Safety Act

Tracked, monitored and reported on White House and Department of Health and Human Services initiatives relative to gene therapy and clinical research oversight and regulation.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

House  
 Senate  
 Department of Health and Human Services/National Institutes of Health

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Marguerite Donoghue Baxter		<input type="checkbox"/>
Sara Milo		<input checked="" type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature \_\_\_\_\_

Printed Name and Title Debra M. Hardy Havens, CEO

Registrant Name Capitol Associates, Inc. Client Name Fred Hutchinson Cancer Research Center

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

H.R. 1057 - Medical Information Privacy Act  
H.R. 1941 - Health Information Privacy Act  
H.R. 2404 - Personal Medical Information Protection Act of 1999  
H.R. 2457/S. 1322 - Genetic Nondiscrimination in Health Insurance and Employment Act of 1999  
H.R. 2470 - Medical Information Protection and Research Enhancement Act of 1999  
H.R. 2878 - Medical Privacy in the Age of New Technologies Act of 1999  
H.R. 4585 - Medical Financial Privacy Protection Act  
S. 573 - Medical Information Privacy and Security Act. Tracked and monitored the rule-making process for medical records privacy.  
H.R. 664/S. 731 - Prescription Drug Fairness for Seniors Act  
H.R. 1885/S. 1191 - International Prescription Drug Parity Act  
H.R. 2927 - Affordable Prescription Drug Act  
H.R. 4680 - Medicare Rx 2000 Act  
H.R. 4770 - Medicare Guaranteed and Health Provider Relief Act of 2000

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New <input type="checkbox"/>
Marguerite Donoghue Baxter		<input type="checkbox"/>
Sara Milo		<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature \_\_\_\_\_

Printed Name and Title Debra M. Hardy Havens, CEO

Form LD-2 (Rev. 06/98)

PAGE 4 of 5

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

21. Client new principal place of business (if different from line 20)

City

State/Zip (or Country)

22. New general description of client's business or activities

**LOBBYIST UPDATE**23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

Becky Levin

Marguerite Donoghue Baxter

**ISSUE UPDATE**24. General lobbying issues previously reported that **no longer** pertain**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client

28. Name of each previously reported foreign entity that **no longer** owns, or controls, or is affiliated with the registrant, client  
or affiliated organization

Signature

Date

Printed Name and Title Debra M. Hardy Havens, CEO

Form LD-2 (Rev. 6/98)

Page 5 of 5